ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japan's Eisai to launch clinical trial for coronavirus treatment

Drugmaker to use once-promising sepsis medication in 500-person test

Eisai will soon start clinical trials in the U.S. for Eritoran. (Photo by Kosaku Mimura)

TOKYO -- Japanese pharmaceutical Eisai is set to begin clinical trials in the U.S. for Eritoran, a drug initially developed as a treatment for severe sepsis but which could be useful in the fight against the new coronavirus, the company announced Wednesday.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more